The Liver Meeting 2019-Molecular Pathogenesis and Management of Hepatocellular Carcinoma

Molecular Pathogenesis and Management of Hepatocellular Carcinoma

Video Transcription

Video Summary

Dr. Josep Maria Llovet, an influential liver cancer researcher, presented on the molecular pathogenesis and management of hepatocellular carcinoma (HCC) in his 2019 lecture. HCC is a significant global health issue, with increasing incidence and mortality rates. The landscape of HCC care has evolved with advancements in systemic therapies, notably the pioneering SHARP trial. Dr. Llovet highlighted the importance of actionable targets in HCC, with only 25% of tumors possessing them. He discussed the molecular drivers, staging systems, and treatment options, emphasizing the need for precision oncology to tailor therapies based on specific biomarkers. While sorafenib remains a standard frontline treatment, recent breakthroughs in immunotherapies, such as nivolumab and pembrolizumab, have shown promise in HCC treatment. Combination therapies, like atezolizumab with bevacizumab and lembatinib with pembrolizumab, are changing the treatment landscape for HCC. Dr. Llovet highlighted the importance of ongoing research, biomarker identification, and the potential for precision oncology to improve outcomes for HCC patients.

Asset Caption

Presenter: Josep M. Llovet

Keywords

Dr. Josep Maria Llovet

Liver cancer researcher

Hepatocellular carcinoma

Molecular pathogenesis

Systemic therapies

Precision oncology

Immunotherapies